Unknown PHASE2 INTERVENTIONAL 5-arm NCT05278338

Efficacy and Safety of JMT103 in the Treatment of Postmenopausal Women With Osteoporosis

A Multicenter, Randomized, Double-blind, Placebo/Positive-controlled Phase II Study to Evaluate the Efficacy and Safety of JMT103 in Postmenopausal Women With Osteoporosis

Sponsor: Shanghai JMT-Bio Inc.

Conditions Postmenopausal Osteoporosis

Interventions Denosumab JMT103 Placebo

Updated 5 times since 2022 Last updated: Jul 14, 2022 Started: Apr 21, 2022 Primary completion: Dec 31, 2023 Completion: Mar 31, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Postmenopausal Osteoporosis and is currently ongoing. Shanghai JMT-Bio Inc. leads this study, which shows 5 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Aug 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Recruiting → Unknown
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE2
Sep 2022 — Jul 2024 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Apr 2022 — Sep 2022 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai JMT-Bio Inc.

Data source: Shanghai JMT-Bio Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Changchun, China